BRAF and thyroid tumor: Ex vivo spiking of PTC thyroid tumor lysates with the specific kinase inhibitor dabrafenib achieved partial differential inhibition of somatic BRAF V600E-positive versus non-BRAF V600E thyroid tumors and of recurrent versus non-recurrent tumors, which was not the case with regorafenib and sorafenib.